聚合順(605166.SH):擬受讓樂清新創持有的山東聚合順30%股權
格隆匯11月3日丨聚合順(605166.SH)公佈,山東聚合順為公司控股子公司,註冊資本2億元人民幣,其中公司認繳1.4億元,持有其70%的股權,樂清新創管理合夥企業(有限合夥)(簡稱“樂清新創”)認繳6000萬元,持有其30%的股權。截至2022年11月3日,鑑於樂清新創對山東聚合順實繳出資為0元,為儘快推進山東聚合順的後續建設和經營,公司擬與樂清新創簽訂《山東聚合順股權轉讓協議》,擬以0元受讓樂清新創對山東聚合順已認繳未實繳的全部註冊資本6000萬元(對應山東聚合順30%的股權)。此次股權受讓後,山東聚合順將成為公司全資子公司,公司對其後續認繳出資的資金來源為公司自有或自籌資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.